Thymulin (FTS-Zn) is a nine-amino-acid thymic hormone whose activity depends entirely on bound zinc. It is one of the few research peptides with randomised double-blind human data — one positive result, one negative — and it is routinely confused with a completely different product. This guide works from the primary papers, the chemical registries and FDA's own lists. Educational reference only, not medical advice.
Standard Access: This compound's three paid filesAll-Access Lifetime: all 55 guides + every printableEducational content only
Thymulin Guide: Available Now
Educational use only — not medical advice. This guide summarizes information reported in published research and community practice for educational purposes. It is not medical advice and not a recommendation to use any compound. Any doses, schedules, or combinations shown are examples of what has been reported, not instructions for you. Many peptides described here are research compounds that are not FDA-approved for the uses discussed and may be investigational or restricted. Effects, risks, and legal status vary; individual needs and results vary. Consult a qualified, licensed healthcare professional before making any decision. Do not use this content to diagnose, treat, or dose yourself.
Thymulin at a glance
What it is
A nonapeptide hormone secreted by thymic epithelial cells (pGlu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn), first called FTS (facteur thymique sérique). The active form holds one zinc ion per peptide, which is why it is written FTS-Zn. PubChem: the INN record nonathymulin is CID 3085284 (C33H54N12O15, 858.9 g/mol, CAS 63958-90-7); both registry masses are for the peptide without its zinc.
Not to be confused with
Thymalin (a thymus-extract preparation from the Russian Khavinson research line), thymosin alpha-1 (28 amino acids) and thymopentin/TP-5. PubChem itself files "Thymalin" as a synonym of the thymulin record, so a registry search on one name returns the other.
Researched for
T-cell differentiation and suppressor T-cell function; trialled in rheumatoid arthritis (1987) and multiple sclerosis (1989); measured in human blood as a marker of zinc status.
Human evidence
Two randomised double-blind placebo-controlled rheumatoid arthritis trials reported significant clinical improvement at 5 mg/day; a randomised double-blind multiple sclerosis pilot trial in 40 patients reported no benefit. Neither has been repeated.
Published trial doses
1, 5 and 10 mg/day were compared in the rheumatoid arthritis trials, with 5 mg/day the most effective arm. These are published trial figures, not recommendations.
Route in the trials
Subcutaneous injection in the multiple sclerosis trial; the rheumatoid arthritis abstract gives daily dosing without stating the route.
Plasma half-life
Never measured in people. The only published figure is from one sheep: injected thymulin was cleared from blood with a half-life of about 10 minutes (J Immunoassay 1994). Treat any human figure found online as unsourced.
Regulatory status
Not approved to treat any condition, anywhere. FDA's 503A compounding list (14 May 2026) places "thymulin acetate" in Category 3, nominated without adequate support; it is not on the 503B list or FDA's safety-risk page. The only US labels naming it are homeopathic dilutions.
Educational reference. This page does not publish dose ranges or reconstitution arithmetic.
What it is / mechanism
Thymulin is a nonapeptide — pyroglutamyl-alanyl-lysyl-seryl-glutaminyl-glycyl-glycyl-seryl-asparagine — produced by the epithelial cells of the thymus. It was first detected as a thymus-dependent activity in blood and named facteur thymique sérique (FTS); in 1977 the Paris group of Jean-François Bach isolated the peptide from pig serum and published its amino-acid sequence (J Biol Chem 1977; PMID 303241 and 914862), which is why PubChem still lists the name "Thymulin (pig peptide moiety)". The defining discovery came five years later. Stripping metal ions from synthetic or natural FTS with a chelating resin abolished its biological activity; adding zinc salts back restored it, best at one zinc ion per peptide molecule, and atomic absorption confirmed zinc in the synthetic peptide. The authors proposed the name thymulin for the zinc-bound, active form (Proc Natl Acad Sci USA 1982; PMID 6957870). So the zinc-free chain is not a weaker version — in that assay it is inactive, and the group's 1989 review states that the peptide's antigenicity depends on the metal as well (Med Oncol Tumor Pharmacother 1989; PMID 2657247). In research settings thymulin is described as inducing T-cell differentiation and modulating the function of T-cell subsets, most consistently suppressor T-cell activity. One consequence matters to anyone checking a product: PubChem holds the sequence twice. The name thymulin resolves to CID 71300623 (CAS 78922-62-0, one stereocentre undefined), while the INN nonathymulin resolves to CID 3085284 (CAS 63958-90-7, UNII 9H198D04WL, all seven stereocentres defined). Both records give C33H54N12O15 and 858.9 g/mol, and neither includes the zinc, so a certificate of analysis matching that mass has confirmed the peptide chain, not the active complex.
Researched effects
The honest summary is that thymulin is far better characterised as a measurement than as a treatment. Most of the human literature does not give thymulin to anyone: it measures the body's own thymulin in blood, and the best-replicated finding is that it falls when zinc is short and recovers when zinc is restored — in volunteers made mildly zinc-deficient by diet, in sickle-cell anaemia, in haemodialysis patients, in Crohn's disease and in children with Down syndrome. That makes it a sensitive marker of zinc status; it does not show that giving thymulin does anything. Where the synthetic peptide was actually given in randomised double-blind trials, the record splits: improvement in rheumatoid arthritis without clear changes in the immune measures the authors tracked, and no effect on any disability measure in multiple sclerosis. Neither trial has been repeated in the 37 years since, although the discoverers' own 1989 review expected thymulin to become a major immunoregulatory drug. A 2026 study linking falling thymulin to age-related inflammation and weaker cancer immunotherapy was done in mice (PMID 42481458). Broad claims about immune restoration, anti-ageing or general immune enhancement have no human trial behind them.
Evidence & regulatory status
Positive human evidence: two randomised, double-blind, placebo-controlled trials of nonathymulin (the synthetic form) in rheumatoid arthritis compared 1, 5 and 10 mg/day (Amor, Dougados, Mery, Dardenne, Bach; Ann Rheum Dis 1987;46(7):549-54; PMID 3310925). The 5 mg/day arm was the most effective, with improvement on the global assessment of all patients entered in 56% versus 17% on placebo (p<0.02) and on four objective parameters, with minimal adverse effects. The clinical effect was not accompanied by clear changes in immunological parameters, although clinical response correlated with the T-cell subset imbalance the authors measured. The highest dose was not the best one.
Negative human evidence: a randomised, double-blind, placebo-controlled pilot trial in 40 matched patients with evolutive multiple sclerosis and moderate disability gave subcutaneous nonathymulin or placebo for 6 months, with a further 6 months of follow-up (Roullet et al., Acta Neurol Scand 1989;80(6):575-8; PMID 2618585). There was no significant difference on the Kurtzke disability scores, the Ambulation Index or the Functional Scale; no significant side effects were recorded; the authors concluded it is not effective in this population.
Zinc, measured in people: in two volunteers made mildly zinc-deficient by diet, six mildly deficient adults with sickle-cell anaemia and six without it, serum thymulin activity fell with the deficiency and was corrected by zinc, in the body and in the test tube, even though plasma zinc itself read normal (Prasad et al., J Clin Invest 1988; PMID 3262625). In nine men on haemodialysis given oral zinc for six months, total thymulin reached normal levels within a week while the zinc-bound, active form rose more slowly over three to six months (J Clin Endocrinol Metab 1989; PMID 2909550). In 27 people with Crohn's disease randomised to two zinc doses or placebo for three months, thymulin rose only in the higher-dose zinc arm (Aliment Pharmacol Ther 1993; PMID 8364132); in 25 children with Down syndrome, four months of dietary zinc normalised low zinc and thymulin levels (Int J Neurosci 1992; PMID 1341688). In none of these studies was anyone given thymulin.
Discovery and zinc dependence: sequence from pig serum (J Biol Chem 1977; PMID 303241, 914862); loss of activity after metal chelation, restoration by zinc at a one-to-one ratio, and the name thymulin (Proc Natl Acad Sci USA 1982; PMID 6957870); activity and antigenicity both zinc-dependent (Bach and Dardenne, Med Oncol Tumor Pharmacother 1989; PMID 2657247).
The 2026 ageing study, and what it tested: a July 2026 paper from the University of Southern California (Kanemaru et al., Nat Commun 2026;17:6534; PMID 42481458) found more pro-inflammatory myeloid cells in aged mice and in older people, identified thymulin as a circulating factor from young animals that dampened that inflammation through NF-kB signalling, and reported that thymulin improved tumour control and response to anti-PD-L1 therapy — in mice. The human part of the study measured the inflammatory cells, not the effect of giving thymulin. It is a strong mechanistic lead, and it is the source of most of the 2026 coverage; it is not evidence that thymulin does anything in a person.
How long it lasts: no human pharmacokinetic study exists. A PubMed search pairing thymulin with pharmacokinetics or half-life returned five records on 24 September 2026, and one contains a measurement: in a paper validating an ELISA for thymulin in farm animals, thymulin injected into a single sheep was cleared from blood with a half-life of 10.3 ± 0.6 minutes (Davis et al., J Immunoassay 1994; PMID 8040352). One animal, one species, route not given in the abstract — a reason to expect short persistence, not a human figure.
No modern trials: ClinicalTrials.gov returns no study with thymulin or nonathymulin as an intervention (the same search returns 758 for semaglutide). A full-text search finds one record, NCT01229579 — zinc supplementation and oral polio vaccine response in 320 infants in Pakistan — in which thymulin is at most a measurement; the peptide is not given.
Regulatory, United States: on FDA's list of bulk substances nominated for pharmacy compounding under section 503A (updated 14 May 2026), "thymulin acetate" is in Category 3 — nominated without adequate support for FDA to evaluate it. It is not on the 503B list for outsourcing facilities (updated 21 March 2025) and not on FDA's page of bulk substances that may present significant safety risks (current as of 22 April 2026), where thymosin alpha-1 is. An openFDA drug-label search for nonathymulin returns three labels, all homeopathic "Thymuline 9C" products; a search for thymulin returns none, and the same search for semaglutide returns 18. No US label describes an injectable thymulin product.
Regulatory, sport: thymulin is not named on the World Anti-Doping Agency's Prohibited List, but "not named" is not "permitted". Section S0 prohibits at all times any pharmacological substance not addressed elsewhere on the list and with no current approval by a government health authority for human therapeutic use.
Research use: sold and handled as a research chemical only; not intended for human or veterinary use, and not approved to treat, cure or prevent any condition.
Research timeline
Dated milestones taken from the primary records: the molecule's discovery, its first registered human study, the trials that shaped the evidence and the regulatory decisions. Each entry links to the record it comes from.
The circulating thymic factor FTS, isolated from pig serum, is sequenced as a nine-amino-acid peptide, and a synthetic copy shows the same biological activity as the natural one. PMID 914862
Three immunodeficient children treated with intravenous synthetic FTS have fewer and milder infections and better cellular immunity, and IgA appears in the two who had none; the gains regress when treatment pauses and return when it restarts. PMID 6124716
FTS is shown to be inactive without zinc and active when one zinc ion binds each peptide; the zinc-bound form is named thymulin (FTS-Zn). PMID 6957870
Two randomized, double-blind, placebo-controlled trials of nonathymulin, the synthetic form, in rheumatoid arthritis find the middle of three dose schedules most effective: 56% of patients improved on the global assessment against 17% on placebo, with minimal side effects. PMID 3310925
A randomized, double-blind, placebo-controlled pilot trial gives 40 matched patients with active multiple sclerosis subcutaneous nonathymulin or placebo for six months: disability, walking and functional scores do not differ, and the authors conclude it is not effective. PMID 2618585
In mice with established allergic asthma, a single inhaled dose of nanoparticles carrying a thymulin-expressing gene normalizes airway inflammation, lung fibrosis and lung mechanics within 20 days. PMID 32577505
FDA's list of bulk substances nominated for compounding, as updated on this date, places thymulin acetate in Category 3, nominated without adequate support. FDA · 503A categories, May 14, 2026
A study in mice identifies thymulin, which declines with age, as a brake on age-related inflammation in myeloid immune cells, and finds it improves tumour control and response to anti-PD-L1 therapy in older animals. PMID 42481458
Records checked Oct 4, 2026
Claims at a glance
The claims most often made about this compound, each with the strongest kind of evidence we found for it. The grade says what was studied, not whether the claim is true; the line beside it says what that study showed.
Regrows hairNo study found. No study has given thymulin to people or animals and measured hair; a 2012 letter on thymic peptides in scalp follicles in a dish has no accessible abstract, so its result is not stated here. PMID 22402437
Strengthens the immune systemHuman, non-randomised. Three children with immune deficiency improved on the synthetic factor in a 1982 case report without a control group; it has never been tested in healthy people. PMID 6124716
Eases rheumatoid arthritisHuman, randomised trial. Two double-blind placebo-controlled trials in 1987 found more patients improved overall on the synthetic form than on placebo; none has followed since. PMID 3310925
Helps multiple sclerosisHuman, randomised trial. A randomised double-blind pilot in 40 patients over six months found no difference from placebo in disability. PMID 2618585
Relieves pain and inflammationAnimal studies only. Rat studies point both ways: given before an inflammatory trigger it reduced pain, but a low dose on its own made rats more sensitive to pain. PMID 10854910
Counters age-related inflammationAnimal studies only. In aged mice it damped inflammatory immune cells and improved tumour control with immunotherapy; no person was given it in that 2026 study. PMID 42481458
The reasoning behind each grade, study by study, is in this guide's Benefit & Outcome Review.
Grades checked Oct 7, 2026
Regulatory status by region
Where this compound stands with the main medicines regulators and in sport. Each line names the record it comes from and the date we read it; where nothing was found, it says where we looked.
United States (FDA)No FDA-approved product: Drugs@FDA lists no approval for thymulin. FDA's 503A list (updated 14 May 2026) places thymulin acetate in Category 3, bulk drug substances nominated without adequate support. Thymulin is not on FDA's compounding safety-risk page (read 18 October 2026). Drugs@FDAFDA 503A categoriesFDA compounding safety risks(read Oct 18, 2026)
European Union (EMA)No EU-wide authorisation: thymulin does not appear in EMA's medicines data (file of 18 October 2026, searched by active substance and by name). EMA medicines data(read Oct 18, 2026)
United Kingdom (MHRA)No UK licence found: thymulin is not in the MHRA products register's index of active substances. MHRA products: substances (T)(read Oct 18, 2026)
Australia (TGA)No Australian registration found: TGA's repository of approved product information returns no document for thymulin. TGA PI/CMI search(read Oct 18, 2026)
Sport (WADA)Not named on the 2026 Prohibited List, but class S0 bans at all times any pharmacological substance without current approval from a government health regulator for human therapeutic use — which takes in thymulin for as long as it has no such approval. WADA Prohibited List 2026 (Trb. 2026, 25)(read Oct 18, 2026)
A printable reference sheet with the compound's key facts, storage guidance and a vial record comes with All-Access Lifetime.
Half-life & pharmacokinetics
No human pharmacokinetic study of thymulin has been published, so there is no human half-life — and specific figures do circulate on commercial pages without a traceable source. The one measured value we found is from an animal: in a 1994 paper validating an ELISA for thymulin in pigs, sheep and cattle, thymulin injected into a single sheep was cleared from blood with a half-life of 10.3 ± 0.6 minutes (Davis et al., J Immunoassay 1994; PMID 8040352). That is one animal, and the abstract does not state the route, so it supports expecting short persistence rather than giving a number for people. The daily schedule in the human trials fits the same picture but is not itself a measurement. Circulating thymulin activity also depends on zinc status, so a blood level reflects zinc as much as the peptide.
Reported side effects & toxicology
The randomised rheumatoid arthritis trials reported minimal adverse effects at 1-10 mg/day, and the multiple sclerosis trial recorded no significant side effects over 6 months of subcutaneous dosing. That is a reassuring short-term signal by the standards of this market — but it comes from two small trials published in 1987 and 1989, and there is no long-term human safety data, no modern pharmacovigilance and no data in healthy subjects rather than patients. FDA has not assessed it either way: its compounding list files thymulin acetate as nominated without adequate support, which is an absence of data, not a finding of safety. As with any injected peptide, injection-site reactions are possible, and material of unverified purity or unverified zinc content carries risks unrelated to the peptide itself.
Storage & handling
Lyophilized (powder): store refrigerated at 2-8C, protected from light; long-term storage is commonly reported in a freezer.
Reconstituted (in bacteriostatic water): refrigerate at 2-8C; swirl gently and do not shake, and do not freeze once mixed. Because the active form is a zinc complex, degradation costs activity as well as content.
References
Primary sources: Amor et al., Nonathymulin in rheumatoid arthritis: two double blind, placebo controlled trials, Ann Rheum Dis 1987 (PMID 3310925); Roullet et al., Nonathymulin treatment of multiple sclerosis: double-blind pilot study, Acta Neurol Scand 1989 (PMID 2618585); the 1977 isolation and sequence of circulating thymic factor from pig serum, J Biol Chem (PMID 303241, 914862); Dardenne et al., Contribution of zinc and other metals to the biological activity of the serum thymic factor, Proc Natl Acad Sci USA 1982 (PMID 6957870); Bach and Dardenne, Thymulin, a zinc-dependent hormone, 1989 (PMID 2657247); Prasad et al., Serum thymulin in human zinc deficiency, J Clin Invest 1988 (PMID 3262625); the zinc studies in haemodialysis (PMID 2909550), Crohn's disease (PMID 8364132) and Down syndrome (PMID 1341688); Davis et al., J Immunoassay 1994 (PMID 8040352). Registries and lists, consulted 24 September 2026: PubChem CID 71300623 and 3085284; MeSH D013935 (Thymic Factor, Circulating); FDA's 503A (14 May 2026) and 503B (21 March 2025) category lists and its compounding safety-risk page (22 April 2026); openFDA drug labels; ClinicalTrials.gov; the WADA Prohibited List. Thymalin is described separately in the Khavinson literature and is not the same substance. Figures are educational, drawn from published studies, not medical advice.
Evidence File
The Thymulin Evidence File: Five Human Reports, All From the 1980s, and Four Decades of Measuring Instead
Thymulin has something most research peptides do not: randomised, double-blind, placebo-controlled trials in people. It also has a problem few of them share: the last time a published study gave it to anyone was 1989. Since then the literature has measured the body's own thymulin — mostly as a sign of zinc status — and tested the peptide, its gene and a related analogue in rodents. This file counts the whole record, sets out every human administration we could find, including three the usual summaries omit, and names the retracted and withdrawn papers that still circulate.
552 PubMed records under thymulin's six names in titles and abstracts
5 published reports of the peptide given to people — the last in 1989
6 of the 10 trial-typed records gave zinc, not thymulin
2 thymulin papers retracted or withdrawn, both from 2009
How large this literature is, and why the usual count is inflated
Every human administration on record
What the other forty years measured: zinc, rodents, a gene and an analogue
The retracted and withdrawn papers, the 2026 mouse study, and what would change the picture
4 more sections in the Evidence File for Thymulin
Unlock the Evidence File, Sourcing File and Benefit & Outcome Review for Thymulin for $14 — or every compound in the library, plus the printable reference sheets, for $99.
The sections above this one stay free to read without an account.
Sourcing File
The Thymulin Sourcing File: A Peptide That Is Inactive Without Its Zinc, and Two Registry Records That Leave the Zinc Out
Thymulin is only active as a complex of the peptide and one zinc ion; strip the zinc and, in the assay that defined it, activity disappears. Both PubChem records for it describe the peptide alone, so a certificate that matches the registry mass has confirmed the chain and said nothing about the zinc. The name is a second trap: the INN record lists "Thymalin", a different product, among its synonyms. This file gives the numbers for both registry records, the masses that separate thymulin from its common impurities and mirror-image variants, and the questions a certificate has to answer.
2 PubChem records, both at 858.9, neither including zinc
7.6% of the peptide's weight in zinc at one ion per molecule
6 PubChem records share thymulin's atoms and bonds
+17.03 Da: the uncyclised N-terminus a certificate should rule out
Identity numbers, and the synonym that points at a different product
The zinc: what a certificate must state, and what a mass spectrum can miss
Impurities and variants that share or nearly share the mass
What to ask a supplier, in order
4 more sections in the Sourcing File for Thymulin
Unlock the Evidence File, Sourcing File and Benefit & Outcome Review for Thymulin for $14 — or every compound in the library, plus the printable reference sheets, for $99.
The sections above this one stay free to read without an account.
Benefit & Outcome Review
The Thymulin Benefit & Outcome Review: Hair, Immunity, Pain and Ageing Claims Against a Record That Stopped in 1989
Thymulin is now sold for hair restoration, immune support, inflammation, pain and "inflammaging". Its controlled human evidence is two things: a 1987 improvement in rheumatoid arthritis and a 1989 null result in multiple sclerosis. Neither is among today's selling points. This review traces each current claim to its source and finds, in turn, no hair study whose result could be verified from accessible material, immune evidence that is mostly about zinc, pain data from rats that points both ways, and an ageing story that is, so far, mice. It also corrects the opposite error: search summaries that say no controlled human trial exists.
0 hair-count or density studies of thymulin found in PubMed or ClinicalTrials.gov, 30 Sep 2026
0 people given thymulin in any study published since 1989
1 randomised result for thymulin in people: rheumatoid arthritis, 1987
0 registered trials of thymulin on ClinicalTrials.gov
Hair restoration: the leading claim with the least behind it
Immune support: what the human data measured, and what it did not
Inflammation, pain and the brain: rat studies that point in both directions
Ageing, cancer and safety: the 2026 mouse study and the 1980s safety record
4 more sections in the Benefit & Outcome Review for Thymulin
Unlock the Evidence File, Sourcing File and Benefit & Outcome Review for Thymulin for $14 — or every compound in the library, plus the printable reference sheets, for $99.
Quick answers about guide scope, access, and educational use context.
Is thymulin the same as Thymalin?
No, and this is the single most common error about it. Thymulin is a defined nine-amino-acid hormone, formerly called FTS, whose activity depends on a bound zinc ion. Thymalin is a thymus-extract preparation from the Russian Khavinson research line, not a single characterised nonapeptide. The confusion is built into the registries: PubChem's nonathymulin record (CID 3085284) lists "Thymalin" among its synonyms, so a search on Thymalin returns thymulin's formula and mass. The two have different structures, different literatures and different evidence. Medibact keeps a separate Thymalin guide for that reason.
Is thymulin the same as thymosin alpha-1?
No. Thymosin alpha-1 is a 28-amino-acid peptide with a substantially larger clinical literature of its own. Thymulin is a nonapeptide — nine residues — and is zinc-dependent, which thymosin alpha-1 is not. They are also treated differently by FDA: thymosin alpha-1 is on its safety-risk page for compounding, thymulin acetate is not. Both are thymic peptides, which is the entire basis for the confusion; evidence for one says nothing about the other.
Why is thymulin written as FTS-Zn?
FTS stands for facteur thymique sérique, its original French name from when it was detected as a thymus-dependent factor in serum; the sequence was published in 1977 from pig serum. The Zn denotes the bound zinc ion. In 1982 the same group showed that removing metal ions abolished the peptide's activity and that adding zinc back restored it, best at one zinc per peptide, and proposed the name thymulin for the zinc-bound form. The zinc-free peptide is inactive rather than merely less potent.
Does thymulin have real human trial data?
Yes, and unusually for this market it includes randomised double-blind placebo-controlled trials — with results going in both directions. Two trials in rheumatoid arthritis reported significant clinical improvement at 5 mg/day (56% global improvement versus 17% on placebo, p<0.02; Ann Rheum Dis 1987). A double-blind pilot trial in 40 people with multiple sclerosis found no benefit on any disability measure and concluded it was not effective in that population (Acta Neurol Scand 1989). Neither result has been repeated, and ClinicalTrials.gov lists no trial giving thymulin.
What dose was used in the human trials?
The rheumatoid arthritis trials compared 1 mg, 5 mg and 10 mg per day of the synthetic form and found 5 mg/day the most effective arm — the highest dose was not the best one. The multiple sclerosis trial used subcutaneous administration over 6 months. These are reported trial figures given for educational context, from studies conducted under clinical supervision in patient populations, and they are not dosing guidance for anyone.
What is thymulin's half-life?
It has never been measured in people. The only published figure is from a single sheep: injected thymulin was cleared from blood with a half-life of about 10 minutes (J Immunoassay 1994). That suggests short persistence but is not a human value, and specific human figures on commercial pages trace back to no primary source. If a number is quoted, ask which study produced it.
What does zinc have to do with thymulin levels?
Almost everything measurable in people. Blood thymulin activity falls with even mild zinc deficiency and recovers when zinc is restored — shown in dietary-deficiency volunteers, sickle-cell anaemia, haemodialysis, Crohn's disease and children with Down syndrome. In those studies people were given zinc, not thymulin. So a low thymulin reading is usually a zinc story, and a thymulin product whose zinc content is not stated cannot be assumed to be the active form.
Is thymulin approved or regulated anywhere?
No regulator has approved it to treat any condition. In the US, FDA's 503A compounding list (updated 14 May 2026) places thymulin acetate in Category 3, nominated without adequate support; it is not on the 503B list or on FDA's safety-risk page. The only US drug labels naming it are homeopathic dilutions ("Thymuline 9C"). It is sold strictly for research purposes, and nothing in this guide is medical advice or an endorsement of human use.
Compliance and trust notes
Educational content only; no personalized health or outcome claims.
No personalized use recommendation outputs.
Use this material for general learning and research-context literacy.
A certificate of analysis (COA) is a laboratory’s report on one sample of one batch. The single most useful thing to know about it is that purity and identity are two separate results that fail in different ways. A high purity figure says the sample was mostly one substance; it does not say that substance was Thymulin. Identity — normally a mass-spectrometry result matching the expected molecular weight — is what establishes what the material actually is, and a certificate reporting purity alone has not answered that question.
Two further limits are worth holding onto. Mass per vial is its own test: a vial can be 99% pure and still contain less material than the label claims. And sterility, endotoxin, heavy metals and residual solvent screening are separately commissioned tests, usually priced individually — so a “third-party tested” badge asserts none of them unless the certificate names them. Check that the batch or lot number on the document matches the vial in front of you; an unmatched certificate describes someone else’s material.
Medibact does not test, endorse or resell peptides, and publishes no rating of any laboratory. How to read a peptide certificate of analysis walks through the document section by section, and what each COA field establishes covers the field-by-field detail and the laboratories that publish their methods.
You’ll need bacteriostatic water
The diluent for reconstituting Thymulin
Reconstitution is volume arithmetic — it assumes a lyophilized vial is dissolved in bacteriostatic water, which is sterile water preserved with 0.9% benzyl alcohol. The preservative is what allows a vial to be entered more than once; plain sterile water carries none and is single-entry by design. Medibact supplies USP-grade Bacteriostatic Water for Injection in a 30 mL multi-dose vial, made in the United States and shipped from the United States, for research use only. One 30 mL vial covers 30 reconstitutions at 1 mL each, 15 at 2 mL, or 10 at 3 mL — division only, not a dosing recommendation.
Educational use only — not medical advice. This guide summarizes information reported in published research and community practice for educational purposes. It is not medical advice and not a recommendation to use any compound. Any doses, schedules, or combinations shown are examples of what has been reported, not instructions for you. Many peptides described here are research compounds that are not FDA-approved for the uses discussed and may be investigational or restricted. Effects, risks, and legal status vary; individual needs and results vary. Consult a qualified, licensed healthcare professional before making any decision. Do not use this content to diagnose, treat, or dose yourself.
